Pharmacogenetics and ethnically targeted therapiesBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7499.1036 (Published 05 May 2005) Cite this as: BMJ 2005;330:1036
- Taslin Rahemtulla, research associate,
- Raj Bhopal, professor of public health ()
- Public Health Sciences, Division of Community Health Sciences, University of Edinburgh, Medical School, Edinburgh EH8 9AG
New drug BiDil marks the return of biology to the debate about race and ethnicity
In modern conceptions of race and ethnicity, biology has been relegated to a minor underlying factor.1 Instead, these concepts have been cast as largely social constructions.2 For example, race traditionally distinguishes between groups according to a mixture of physical characteristics (including skin colour), which reflect ancestry and hence biology. A modern conception of race would place the emphasis on a common social and political heritage. Similarly, ethnicity puts emphasis on distinguishing between groups by using a mixture of cultural factors, including language and religion.2 Recent developments in pharmacogenetics, however, renew the historical emphasis on biology in concepts of race and ethnicity. Pharmacogeneticists examine whether different responses to drug treatment may be attributable to genetic differences. They are focusing on race and ethnicity as a means to this end. A recent international conference, the 8th world congress on clinical pharmacology and therapeutics, in Brisbane, Australia, had an afternoon on ethnopharmacology, showing how seriously this new subject is being taken.3
In the middle of this resurgence of the role of biology in concepts of race and ethnicity comes BiDil, a new drug treatment for heart failure tested solely in one particular racial group. In 2001 NitroMed began the African-American heart failure trial (A-HeFT), the first heart failure trial conducted exclusively in African-American patients, claiming that “observed racial disparities in mortality and therapeutic response rates in Black heart failure patients may be due in part to ethnic differences in the underlying pathophysiology of heart failure.”4 5 The study found that BiDil (a fixed dose of isosorbide dinitrate and hydralazine, designed to restore low or depleted nitric oxide concentrations to the blood) combined with standard therapy for heart failure reduced mortality by 43% among black patients.5 Hailed by the media as the first ethnic drug, BiDil is reported to be on the way to becoming the first drug approved by the US Food and Drug Administration to treat heart failure in African-American patients only.6
The major implication of BiDil is that differential responses to treatment between racial groups, defined by using ostensibly social categories (here, patients self reported to be African-Americans), are attributed primarily to genetic differences. If this is shown to be true it will undermine a postwar consensus emphasising the social construction of race and ethnicity. Largely social categories of race and ethnicity may be useful indicators of genetic variations because they are at least partly based on biological characteristics. If everyone were the same physically—skin colour and so on—racial and ethnic categories would not exist. This raises fundamental and controversial questions. Do important genetic differences exist between ethnic and racial groups as defined by current classifications? If they do, how good are current racial labels as an indicator of these genetic differences? Should such classifications be used in this way? If so, will race science see a resurgence?1
Many researchers and policy makers argue against the use of racial or ethnic categories in medicine, saying that classifying people according to race and ethnicity reinforces existing social divisions in society or leads to discriminatory practices.7 Others cite research showing that genetic differences are greater within socially defined racial groups than between groups.8 The relation between features that traditionally define race and contribute to ethnicity, such as skin colour, and genetic differences has been found to be inconsistent.9 In addition, by focusing on biological factors as the explanation for differences in response to drugs, researchers risk ignoring other possible environmental, psychosocial, and economic factors, and lifestyle factors such as diet, that are important in producing illness.7 If important genetic variations exist between currently defined racial and ethnic groups, drug treatments may be tailored for greater effect.
In a review of the research on the effects of cardiovascular therapies carried out by Taylor and Ellis,10 the evidence for ethnic variations in response to such drugs seems modest—a conclusion we reached in our own review in July 2004 and presented at the conference in Brisbane.3 Diuretics were found to be beneficial for both black and white patients with heart failure. Black patients were found to respond equally well to angiotensin receptor blockers, spironolactone, digoxin, and carvedilol (β-adrenoceptor antagonists). Compared with white patients, black patients were found to respond less well to angiotensin converting enzyme inhibitors (enalapril),10 though this conclusion has been contested. Yu et al showed that Chinese patients required lower dosages of heparin and warfarin than those usually recommended for white patients.11 12
The new genetics has reopened the debate on the biological basis of race and ethnicity. Pharmacogenetics is growing fast, and it will lead to a more refined understanding of ethnic and racial differences in drug response. Many claims and counterclaims will be made. Doctors need to take an open minded but critical stance. A historical perspective is likely to be helpful—claims of a biological basis to racial or ethnic variations in health and disease, including therapeutics, have proved to be overstated.1
Competing interests RSB was an invited speaker at the 8th world congress on clinical pharmacology and therapeutics, giving a presentation on concepts of ethnicity and race, and his expenses were met by both the congress and the James Lance GlaxoSmithKline Medicines Research Unit in Sydney.